Kyowa Kirin buys back Tivozanib non-oncology rights from AVEO Oncology

This article was originally published here

The agreement is an amendment to the terms of the 2006 tivozanib license agreement between Kyowa Kirin and AVEO which granted AVEO exclusive rights of tivozanib in all

The post Kyowa Kirin buys back Tivozanib non-oncology rights from AVEO Oncology appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply